[go: up one dir, main page]

PE20070645A1 - HETEROCYCLIC COMPOUNDS AS BETA-SECRETASE MODULATORS - Google Patents

HETEROCYCLIC COMPOUNDS AS BETA-SECRETASE MODULATORS

Info

Publication number
PE20070645A1
PE20070645A1 PE2006001476A PE2006001476A PE20070645A1 PE 20070645 A1 PE20070645 A1 PE 20070645A1 PE 2006001476 A PE2006001476 A PE 2006001476A PE 2006001476 A PE2006001476 A PE 2006001476A PE 20070645 A1 PE20070645 A1 PE 20070645A1
Authority
PE
Peru
Prior art keywords
beta
acetamide
tetrahydro
alkenyl
amino
Prior art date
Application number
PE2006001476A
Other languages
Spanish (es)
Inventor
Wenge Zhong
Stephen Hitchcock
Brian K Albrecht
Michael Bartberger
James Brown
Ryan Brown
Stuart Charles Chaffee
Yuan Cheng
Michael Croghan
Russell Graceffa
Scott Harried
Dean Hickman
Daniel Horne
Randall W Hungate
Ted Judd
Matthew Kaller
Charles Kreiman
Daniel La
Patricia Lopez
Craig E Masse
Holger Monenschein
Thomas Nguyen
Thomas Nixey
Vinod F Patel
Lewis Pennigton
Matthew Weiss
Qiufen Xue
Bryant Yang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20070645A1 publication Critical patent/PE20070645A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE A ES ALQUILO(C1-C10), ALQUENILO(C2-C10), ALQUINILO(C2-C10), ENTRE OTROS; W ES -C(=O)-, -OC(=O)-, -NHC(=O)-, ENTRE OTROS; B ES R2-(CR2aR2a)h-, R2-O-(CR2aR2a)h, ENTRE OTROS, DONDE R2 ES ALQUILO(C1-C10), HALOALQUILO(C1-C10), ALQUENILO(C2-C10), ENTRE OTROS; R2a ES H, OH, NO2, CN, ENTRE OTROS; h ES DE 0 A 3; i ES DE 1 A 3; j ES DE 0 A 2; R3 ES H, CN, ALQUILO(C1-C10), ENTRE OTROS; R4 ES H, CN, ALQUENILO(C2-C10), ENTRE OTROS; R5 ES UN COMPUESTO DE FORMULA (a), (b), (c), ENTRE OTROS; DONDE X1 ES CR12, O, S O NR12; X2 ES CR12R12; Y1, Y2 E Y3 SON CADA UNO CR12R12, O, S O NR12; m ES DE 0 A 2; o ES DE 0 A 5; R10 ES H, HALO, CN, OH, ENTRE OTROS; R12 ES H, HALO, NH2, NO2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-((1S,2R)-2-HIDROXI-1-(FENILMETIL)-3-(((4S)-2,6,6-TRIMETIL-4,5,6,7-TETRAHIDRO-1-BENZOFURAN-4-IL)AMINO)PROPIL)ACETAMIDA, N-((1S,2R)-3-(((4S)-2-ETIL-6,6-DIMETIL-4,5,6,7-TETRAHIDRO-1-BENZOTIEN-4-IL)AMINO)-2-HIDROXI-1-(FENILMETIL)PROPIL)-2-(2-OXO-1-PIRROLIDINIL)ACETAMIDA, N-((1S,2R)-1-((3-CIANOFENIL)METIL)-3-(((1R)-3,3-DIMETIL-7-(METILOXI)-4-OXO-1,2,3,4-TETRAHIDRO-1-NAFTALENIL)AMINO)-2-HIDROXIPROPIL)-2-(METILOXI)ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE LA ENZIMA BETA-SECRETASA SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMERREFERS TO COMPOUNDS OF FORMULA (I) WHERE A IS ALKYL (C1-C10), ALKENYL (C2-C10), ALKINYL (C2-C10), AMONG OTHERS; W IS -C (= O) -, -OC (= O) -, -NHC (= O) -, AMONG OTHERS; B IS R2- (CR2aR2a) h-, R2-O- (CR2aR2a) h, AMONG OTHERS, WHERE R2 IS ALKYL (C1-C10), HALOALKYL (C1-C10), ALKENYL (C2-C10), AMONG OTHERS; R2a IS H, OH, NO2, CN, AMONG OTHERS; h IS 0 TO 3; i IS FROM 1 TO 3; j IS FROM 0 TO 2; R3 IS H, CN, (C1-C10) ALKYL, AMONG OTHERS; R4 IS H, CN, ALKENYL (C2-C10), AMONG OTHERS; R5 IS A COMPOUND OF FORMULA (a), (b), (c), AMONG OTHERS; WHERE X1 IS CR12, O, S OR NR12; X2 IS CR12R12; Y1, Y2 AND Y3 ARE EACH CR12R12, O, S OR NR12; m IS 0 TO 2; o IS FROM 0 TO 5; R10 IS H, HALO, CN, OH, AMONG OTHERS; R12 IS H, HALO, NH2, NO2, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: N - ((1S, 2R) -2-HYDROXY-1- (PHENYLMETHYL) -3 - (((4S) -2,6,6-TRIMETHYL-4,5,6,7-TETRAHYDRO-1 -BENZOFURAN-4-IL) AMINO) PROPYL) ACETAMIDE, N - ((1S, 2R) -3 - (((4S) -2-ETHYL-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO- 1-BENZOTHEN-4-IL) AMINO) -2-HYDROXY-1- (PHENYLMETHYL) PROPYL) -2- (2-OXO-1-PYRROLIDINYL) ACETAMIDE, N - ((1S, 2R) -1 - ((3 -CYANOPHENYL) METHYL) -3 - (((1R) -3,3-DIMETHYL-7- (METHYLOXY) -4-OXO-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL) AMINO) -2-HYDROXYPROPIL ) -2- (METHYLOXY) ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE MODULATORS OF THE BETA-SECRETASE ENZYME, BEING USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE

PE2006001476A 2005-11-21 2006-11-20 HETEROCYCLIC COMPOUNDS AS BETA-SECRETASE MODULATORS PE20070645A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73910805P 2005-11-21 2005-11-21
US85482406P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
PE20070645A1 true PE20070645A1 (en) 2007-08-24

Family

ID=39708735

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001476A PE20070645A1 (en) 2005-11-21 2006-11-20 HETEROCYCLIC COMPOUNDS AS BETA-SECRETASE MODULATORS

Country Status (8)

Country Link
EP (1) EP1971598A1 (en)
JP (1) JP5274258B2 (en)
AR (1) AR057985A1 (en)
AU (1) AU2006316620B2 (en)
CA (1) CA2629402C (en)
PE (1) PE20070645A1 (en)
TW (1) TW200800966A (en)
WO (1) WO2007061670A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200901991A (en) * 2007-05-25 2009-01-16 Amgen Inc Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
MX2009012608A (en) * 2007-05-25 2009-12-07 Amgen Inc Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use.
US8946483B2 (en) 2011-07-21 2015-02-03 Ge Healthcare Limited Precursor compounds and methods for making same
BR112014023384A8 (en) * 2012-03-20 2018-01-16 R Artis Dean spirocyclic bace inhibitors of dihydro-thiazine and dihydro-oxazine, and compositions and uses thereof.
EP3170820B1 (en) 2014-07-16 2019-02-20 Japan Science and Technology Agency Benzothiazole compound and medicine containing same
JP7413346B2 (en) 2019-03-06 2024-01-15 第一三共株式会社 Pyrrolopyrazole derivative

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
ATE314343T1 (en) 2000-06-30 2006-01-15 Elan Pharm Inc COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
JP2005500319A (en) 2001-06-27 2005-01-06 イーラン　ファーマスーティカルズ、インコーポレイテッド Β-hydroxyamine derivatives useful for the treatment of Alzheimer's disease
KR100713137B1 (en) 2001-06-28 2007-05-02 동화약품공업주식회사 Novel 2,4-difluorobenzamide derivatives
BR0211118A (en) 2001-07-10 2004-10-26 Elan Pharm Inc Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
BR0211122A (en) 2001-07-10 2004-10-26 Elan Pharm Inc Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
MXPA04000334A (en) 2001-07-11 2004-09-28 Elan Pharm Inc N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds.
MXPA04003245A (en) 2001-10-04 2004-08-11 Elan Pharm Inc Hydroxypropylamines.
BR0213138A (en) 2001-10-05 2004-08-24 Elan Pharm Inc Methods of treating or preventing alzheimer's disease and a disease distinguished by beta-amyloid deposition in the brain, treating a patient who has, or preventing a patient from contracting a disease or condition, producing a beta-secretase complex and inhibit beta-amyloid plaque production in an animal, composition and use of a compound
MXPA04004079A (en) 2001-10-29 2005-07-05 Pharmacia & Upjohn Co Llc Hydroxy substituted amides for the treatment of alzheimer's disease.
RS50504A (en) 2001-11-08 2007-04-10 Elan Pharmaceuticals Inc., N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives
AR037460A1 (en) 2001-11-30 2004-11-10 Smithkline Beecham Plc HYDROXYETHYLENE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR PREPARATION
BR0214736A (en) 2001-12-06 2004-11-23 Elan Pharm Inc Compound and its pharmaceutically acceptable salts, pharmaceutical composition and method of treating humans or animals suffering from diseases or conditions
BR0306724A (en) 2002-01-04 2006-04-11 Elan Pharm Inc amino substituted carboxamides for treatment of alzheimer's disease
JP2005526714A (en) 2002-01-17 2005-09-08 ニューロジェン・コーポレーション Substituted quinazolin-4-ylamine analogs as modulators of capsaicin
EP1515944A1 (en) 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115747B2 (en) 2002-06-20 2006-10-03 Pharmacia & Upjohn Company Process for preparing oxazole intermediates
UY27967A1 (en) 2002-09-10 2004-05-31 Pfizer 2-HINDROXI-1,3-DIAMINOALCANE OIL
US7362070B2 (en) 2002-11-04 2008-04-22 Hamilton Sundstrand Corporation Electric motor control system including position determination and error correction
EP1562897B1 (en) 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
CA2507484A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
CA2512111A1 (en) 2003-01-07 2004-07-29 Merck And Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
CA2518886A1 (en) 2003-03-14 2004-09-23 Merck Sharp & Dohme Limited Method for treating mild cognitive impairment and for preventing or delaying alzheimer's disease
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
BRPI0409627A (en) 2003-04-21 2006-04-25 Elan Pharm Inc Phenacyl 2-hydroxy-3-diaminoalkanes
TW200512195A (en) 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
AU2003297826A1 (en) 2003-06-16 2005-01-28 Sunesis Pharmaceuticals, Inc Aspartyl protease inhibitors
WO2005004802A2 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
EP1643986A4 (en) 2003-07-01 2009-04-08 Merck & Co Inc PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
CA2553973A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
JP2007528403A (en) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド Methods for treating amyloidosis using bicyclic aspartic protease inhibitors
BRPI0509186A (en) * 2004-03-25 2007-08-28 Elan Pharm Inc 2-amino-and 2-thio-substituted 1,3-diaminopropanes

Also Published As

Publication number Publication date
AU2006316620A1 (en) 2007-05-31
CA2629402A1 (en) 2007-05-31
CA2629402C (en) 2011-07-26
AR057985A1 (en) 2008-01-09
AU2006316620B2 (en) 2011-03-03
EP1971598A1 (en) 2008-09-24
TW200800966A (en) 2008-01-01
WO2007061670A1 (en) 2007-05-31
JP5274258B2 (en) 2013-08-28
JP2009516684A (en) 2009-04-23

Similar Documents

Publication Publication Date Title
RU2418792C2 (en) Azole compounds with neutrotherapeutic activity
EE200300403A (en) N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical
EA200700117A1 (en) N-SUBSTITUTED PIPERIDINES AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS
NO20062677L (en) Benzyl etheramine compounds useful as CCR-5 antagonists
ATE360631T1 (en) AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR
PE20061124A1 (en) COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINE
PE20121354A1 (en) HEPATITIS C VIRUS INHIBITORS
ATE370141T1 (en) ANTIDIABETIC HETEROCYCLIC BETA-AMINO COMPOUNDS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE
DE60316416D1 (en) HETEROCYCLIC BETA-AMINO COMPOUNDS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE FOR TREATMENT OR PREVENTION OF DIABETES
UY27368A1 (en) NEW COMPOUNDS
ATE506951T1 (en) TERTIARY CARBINAMINES ACTIVE AS INHIBITORS OF BETA-SECRETASE WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PE20050420A1 (en) PHENACILO 2-HYDROXY-3-DIAMINOALKANOS
BRPI0409227B8 (en) "compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (i)"
BR0012804A (en) Amine and amide derivatives as ligands for the neuropeptide receptor y5 useful in the treatment of obesity and other disorders
PE20110367A1 (en) DERIVATIVES OF 4-CYANO-4-PHENYL-PYRROLIDIN-2-CARBOXAMIDES SUBSTITUTED AS INHIBITORS OF THE INTERACTION p53-MDM2
EA200700489A1 (en) NEW BENZO-CONDENSED HETEROARYL SULFAMIDE DERIVATIVES, USEFUL AS ANTI-CONVOLTIVE AGENT
EP1615914A4 (en) ANTAGONISTS OF CGRP RECEPTORS
BR0310077A (en) New compounds and their use
TNSN06109A1 (en) BICYCLIC [3.1.0] DERIVATIVES AS INHIBITORS OF THE GLYCINE CARRIER
DK1776349T3 (en) 2-Amino-Puinazoline Derivatives Usable as Inhibitors of Beta-Secretase (BACE)
ATE517861T1 (en) BENZYL ETHER AND BENZYLAMIN COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
RU2394031C2 (en) Quaternary ammonium salts as m3 antagonists
TW200512201A (en) New heterocyclic amides
AR029343A1 (en) USE OF A LOW AFFINITY NMDA ANTAGONIST FOR THE TREATMENT OF DEPRESSION

Legal Events

Date Code Title Description
FD Application declared void or lapsed